Imunon Scheduled to Announce Q4 Earnings on March 30
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy IMNN?
Source: seekingalpha
- Earnings Announcement: Imunon (IMNN) is set to announce its Q4 earnings on March 30 before the market opens, with a consensus EPS estimate of -$1.82, indicating ongoing challenges in profitability.
- Earnings Performance: Over the past year, IMNN has failed to beat EPS estimates 0% of the time, reflecting a lack of confidence in its earnings potential, which could negatively impact its stock price.
- Revenue Estimate Revisions: In the last three months, EPS estimates have seen two upward revisions with no downward adjustments; however, this has not alleviated the market's pessimistic outlook on the company's profitability, suggesting analysts remain skeptical about future performance.
- Quantitative Rating Analysis: According to Seeking Alpha's Quant Rating, Imunon's financial performance and market outlook remain poor, potentially exacerbating investor concerns regarding its future growth prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMNN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMNN
Wall Street analysts forecast IMNN stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.720
Low
12.00
Averages
12.00
High
12.00
Current: 2.720
Low
12.00
Averages
12.00
High
12.00
About IMNN
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Imunon Scheduled to Announce Q4 Earnings on March 30
- Earnings Announcement: Imunon (IMNN) is set to announce its Q4 earnings on March 30 before the market opens, with a consensus EPS estimate of -$1.82, indicating ongoing challenges in profitability.
- Earnings Performance: Over the past year, IMNN has failed to beat EPS estimates 0% of the time, reflecting a lack of confidence in its earnings potential, which could negatively impact its stock price.
- Revenue Estimate Revisions: In the last three months, EPS estimates have seen two upward revisions with no downward adjustments; however, this has not alleviated the market's pessimistic outlook on the company's profitability, suggesting analysts remain skeptical about future performance.
- Quantitative Rating Analysis: According to Seeking Alpha's Quant Rating, Imunon's financial performance and market outlook remain poor, potentially exacerbating investor concerns regarding its future growth prospects.
See More
Biotech Landscape Update: Regulatory Approvals and Mergers
- Anavex Drug Withdrawal: Anavex Life Sciences Corp. (AVXL) withdrew its EU marketing application for Alzheimer's drug Blarcamesine after the EMA's CHMP indicated it could not issue a positive opinion, marking a significant setback for the company's lead candidate despite continued support from patient groups.
- Quoin FDA Alignment: Quoin Pharmaceuticals Ltd. (QNRX) received positive feedback from the FDA confirming that a single Phase 3 trial may suffice for U.S. approval of QRX003 for Netherton Syndrome, with plans to initiate Phase 3 in 2026 and potentially file an NDA in 2027.
- Corcept Drug Approval: Corcept Therapeutics Inc. (CORT) secured FDA approval for Lifyorli combined with nab-paclitaxel to treat platinum-resistant ovarian cancer, based on Phase 3 ROSELLA trial results involving 381 patients, marking the first FDA-approved selective glucocorticoid receptor antagonist.
- Merck Acquires Terns: Merck (MRK) announced a definitive agreement to acquire Terns Pharmaceuticals for $53.00 per share, totaling approximately $6.7 billion, which is expected to enhance Merck's presence in hematology, with the transaction anticipated to close in Q2 2026.
See More
IMUNON Secures $7 Million from Institutional Investor in Direct Stock Offering
- Financing Agreement Reached: IMUNON has entered into a securities purchase agreement with a healthcare-focused institutional investor to sell 1,939,114 shares of common stock and associated warrants, with expected gross proceeds of approximately $7 million, enhancing the company's liquidity to support its clinical-stage immunotherapy development.
- Warrant Details: Each share is priced at $3.61, with warrants having an exercise price of $3.482, which will be exercisable immediately and expire in five years, providing the company with additional capital sources to drive future R&D efforts.
- Market Reaction Anticipated: The offering is expected to close on December 31, 2025, and if successful, will help IMUNON maintain compliance with Nasdaq requirements and avoid potential delisting risks, thereby boosting investor confidence.
- Registration Statement Background: The securities are being offered under a Form S-3 registration statement declared effective on May 22, 2024, ensuring compliance and laying the groundwork for future financing activities, demonstrating the company's flexibility and adaptability in capital markets.
See More
IMUNON Advances OVATION3 Study, Aiming for Breakthrough Therapy
- Significant Clinical Progress: IMUNON initiated its pivotal Phase 3 OVATION3 study in 2025, evaluating IMNN-001 in combination with standard chemotherapy, demonstrating strong clinical momentum that could redefine treatment standards for ovarian cancer.
- Survival Extension: The Phase 2 OVATION2 study revealed a 13-month median overall survival extension in the intent-to-treat population with IMNN-001, and in patients receiving PARP inhibitors, the median survival has not yet been reached, indicating its potential therapeutic advantage.
- Immunotherapy Promise: New data indicates that IMNN-001 activates the tumor microenvironment, leading to IL-12 production and enhanced T cell functions, showcasing its broad applicability in frontline ovarian cancer treatment.
- Financial Discipline: IMUNON maintained financial discipline in 2025, planning to invest $30 million in the OVATION3 trial, reflecting the company's confidence in its R&D and market opportunities.
See More
IMUNON Advances OVATION3 Study, Aiming for Breakthrough Therapy
- Significant Clinical Progress: IMUNON initiated its pivotal Phase 3 OVATION 3 study in 2025, evaluating IMNN-001 in combination with standard chemotherapy, demonstrating strong clinical outcomes that could redefine treatment standards for ovarian cancer.
- Survival Extension: In the Phase 2 OVATION 2 study, IMNN-001 showed a 13-month median overall survival extension in the intent-to-treat population, with survival not yet reached in patients receiving PARP inhibitors, indicating its potential in ovarian cancer treatment.
- Promise of Immunotherapy: New data indicates that IMNN-001 activates macrophages in the tumor microenvironment, leading to IL-12 production and enhanced T cell cytotoxic functions, showcasing its promise as a frontline therapy.
- Financial Discipline: IMUNON maintained financial discipline in 2025, planning to invest $30 million in the OVATION 3 trial, reflecting the company's confidence in future growth and commitment to shareholder value.
See More
Imunon (IMNN) Q3 2025 Earnings Conference Call Transcript
- Author's Perspective: The views and opinions presented are solely those of the author.
- No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
See More
Imunon Scheduled to Announce Q4 Earnings on March 30
- Earnings Announcement: Imunon (IMNN) is set to announce its Q4 earnings on March 30 before the market opens, with a consensus EPS estimate of -$1.82, indicating ongoing challenges in profitability.
- Earnings Performance: Over the past year, IMNN has failed to beat EPS estimates 0% of the time, reflecting a lack of confidence in its earnings potential, which could negatively impact its stock price.
- Revenue Estimate Revisions: In the last three months, EPS estimates have seen two upward revisions with no downward adjustments; however, this has not alleviated the market's pessimistic outlook on the company's profitability, suggesting analysts remain skeptical about future performance.
- Quantitative Rating Analysis: According to Seeking Alpha's Quant Rating, Imunon's financial performance and market outlook remain poor, potentially exacerbating investor concerns regarding its future growth prospects.
See More
Biotech Landscape Update: Regulatory Approvals and Mergers
- Anavex Drug Withdrawal: Anavex Life Sciences Corp. (AVXL) withdrew its EU marketing application for Alzheimer's drug Blarcamesine after the EMA's CHMP indicated it could not issue a positive opinion, marking a significant setback for the company's lead candidate despite continued support from patient groups.
- Quoin FDA Alignment: Quoin Pharmaceuticals Ltd. (QNRX) received positive feedback from the FDA confirming that a single Phase 3 trial may suffice for U.S. approval of QRX003 for Netherton Syndrome, with plans to initiate Phase 3 in 2026 and potentially file an NDA in 2027.
- Corcept Drug Approval: Corcept Therapeutics Inc. (CORT) secured FDA approval for Lifyorli combined with nab-paclitaxel to treat platinum-resistant ovarian cancer, based on Phase 3 ROSELLA trial results involving 381 patients, marking the first FDA-approved selective glucocorticoid receptor antagonist.
- Merck Acquires Terns: Merck (MRK) announced a definitive agreement to acquire Terns Pharmaceuticals for $53.00 per share, totaling approximately $6.7 billion, which is expected to enhance Merck's presence in hematology, with the transaction anticipated to close in Q2 2026.
See More
IMUNON Secures $7 Million from Institutional Investor in Direct Stock Offering
- Financing Agreement Reached: IMUNON has entered into a securities purchase agreement with a healthcare-focused institutional investor to sell 1,939,114 shares of common stock and associated warrants, with expected gross proceeds of approximately $7 million, enhancing the company's liquidity to support its clinical-stage immunotherapy development.
- Warrant Details: Each share is priced at $3.61, with warrants having an exercise price of $3.482, which will be exercisable immediately and expire in five years, providing the company with additional capital sources to drive future R&D efforts.
- Market Reaction Anticipated: The offering is expected to close on December 31, 2025, and if successful, will help IMUNON maintain compliance with Nasdaq requirements and avoid potential delisting risks, thereby boosting investor confidence.
- Registration Statement Background: The securities are being offered under a Form S-3 registration statement declared effective on May 22, 2024, ensuring compliance and laying the groundwork for future financing activities, demonstrating the company's flexibility and adaptability in capital markets.
See More
IMUNON Advances OVATION3 Study, Aiming for Breakthrough Therapy
- Significant Clinical Progress: IMUNON initiated its pivotal Phase 3 OVATION3 study in 2025, evaluating IMNN-001 in combination with standard chemotherapy, demonstrating strong clinical momentum that could redefine treatment standards for ovarian cancer.
- Survival Extension: The Phase 2 OVATION2 study revealed a 13-month median overall survival extension in the intent-to-treat population with IMNN-001, and in patients receiving PARP inhibitors, the median survival has not yet been reached, indicating its potential therapeutic advantage.
- Immunotherapy Promise: New data indicates that IMNN-001 activates the tumor microenvironment, leading to IL-12 production and enhanced T cell functions, showcasing its broad applicability in frontline ovarian cancer treatment.
- Financial Discipline: IMUNON maintained financial discipline in 2025, planning to invest $30 million in the OVATION3 trial, reflecting the company's confidence in its R&D and market opportunities.
See More
IMUNON Advances OVATION3 Study, Aiming for Breakthrough Therapy
- Significant Clinical Progress: IMUNON initiated its pivotal Phase 3 OVATION 3 study in 2025, evaluating IMNN-001 in combination with standard chemotherapy, demonstrating strong clinical outcomes that could redefine treatment standards for ovarian cancer.
- Survival Extension: In the Phase 2 OVATION 2 study, IMNN-001 showed a 13-month median overall survival extension in the intent-to-treat population, with survival not yet reached in patients receiving PARP inhibitors, indicating its potential in ovarian cancer treatment.
- Promise of Immunotherapy: New data indicates that IMNN-001 activates macrophages in the tumor microenvironment, leading to IL-12 production and enhanced T cell cytotoxic functions, showcasing its promise as a frontline therapy.
- Financial Discipline: IMUNON maintained financial discipline in 2025, planning to invest $30 million in the OVATION 3 trial, reflecting the company's confidence in future growth and commitment to shareholder value.
See More
Imunon (IMNN) Q3 2025 Earnings Conference Call Transcript
- Author's Perspective: The views and opinions presented are solely those of the author.
- No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
See More
